Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 40 Show results per page	View Search Criteria \| Help With Results

Last Modified: 10/31/2008 First Published: 3/22/2007


1.		Phase II/III Randomized Study of Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Biomarker/Laboratory analysis, Treatment				Active				Any age				Other				UHW-AML16 EU-20677, ISRCTN11036523, EUDRACT-2005-002846-14, MREC-CU106, NCT00454480


2.		Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-Azacitidine (Vidaza®)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 120				Other				TUD-RELAZA-008 2006-001040-31 (EudraCT Nr.), NCT00422890

Last Modified: 5/22/2007 First Published: 9/23/2005


3.		Phase I/II Study of Azacitidine in Combination With Arsenic Trioxide in Patients With Myelodysplastic Syndromes

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				UCLA-0408087 NCT00234000

Last Modified: 11/2/2006 First Published: 10/6/2006


4.		Phase I/II Study of Azacitidine and MS-275 in Patients With Recurrent Advanced Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				JHOC-J0658 7759, NCI-7759, JHOC-NA_00003114, NCT00387465

Last Modified: 4/24/2008 First Published: 10/21/2006


5.		Phase I/II Study of Vorinostat (SAHA) and Azacitidine in Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				NYCC-6898 6898, NCI-6898, NCT00392353

First Published: 7/13/2007


6.		Phase I/II Study of Azacitidine, Docetaxel, and Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Natural history/Epidemiology, Treatment				Active				18 and over				Other, Pharmaceutical / Industry				SCCC-2006080 SCCC 2006080, SCCC-EPROST-20061143, WIRB-20070344, PHARMION-SCCC-2006080, NCT00503984


7.		Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				Not specified				Other				2007-0030 NCT00529022


8.		Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory AML or High Risk MDS

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				2005-0291 NCT00569010


9.		A Phase I/II Clinical Trial of Vidaza With Abraxane in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				19 and over				Other				VAST-B NCT00748553


10.		A Phase I/II Trial of the Combination 5-Azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 to 90				Other, Pharmaceutical / Industry				050938 NCT00766116

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute